腰带与吊带：疫苗和替沙格韦单抗/西加韦单抗在免疫功能低下患者中预防 COVID-19 的应用。
Belt and Suspenders: Vaccines and Tixagevimab/Cilgavimab for Prevention of COVID-19 in Immunocompromised Patients.
机构信息
Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusettes (C.N.K.).
出版信息
Ann Intern Med. 2022 Jun;175(6):892-894. doi: 10.7326/M22-1026. Epub 2022 Apr 12.
Abstract
On 8 December 2021, the U.S. Food and Drug Administration issued an emergency use authorization for AstraZeneca's Evusheld (tixagevimab copackaged with cilgavimab, administered as concomitant injections) for the prevention of COVID-19 in those who are moderately to severely compromised, are aged 12 years or older, and weigh more than 40 kg. This commentary discusses current appropriate use of this important preventive intervention.
摘要
2021 年 12 月 8 日，美国食品和药物管理局发布了阿斯利康 Evusheld（替沙格韦单抗与西加韦单抗联合包装，作为同时注射给药）的紧急使用授权，用于预防中度至重度免疫功能低下者、12 岁及以上且体重超过 40 公斤的人群感染 COVID-19。本评论讨论了这一重要预防干预措施的当前合理使用。
相似文献
1
Belt and Suspenders: Vaccines and Tixagevimab/Cilgavimab for Prevention of COVID-19 in Immunocompromised Patients.腰带与吊带：疫苗和替沙格韦单抗/西加韦单抗在免疫功能低下患者中预防 COVID-19 的应用。
Ann Intern Med. 2022 Jun;175(6):892-894. doi: 10.7326/M22-1026. Epub 2022 Apr 12.
2
Systematic review and meta-analysis of the clinical effectiveness of tixagevimab/cilgavimab for prophylaxis of COVID-19 in immunocompromised patients.系统评价和荟萃分析：替沙格韦单抗/西加韦单抗用于预防免疫功能低下患者 COVID-19 的临床效果。
Br J Haematol. 2023 Jun;201(5):813-823. doi: 10.1111/bjh.18782. Epub 2023 Apr 3.
3
Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review.替沙格韦单抗/西加韦单抗用于 COVID-19 的预防和治疗：综述。
Expert Rev Anti Infect Ther. 2022 Dec;20(12):1517-1527. doi: 10.1080/14787210.2022.2134118. Epub 2022 Oct 27.
4
Safety and Efficacy of Intramuscular Tixagevimab-Cilgavimab in Prevention of COVID-19 in Patients Who Are Immunocompromised.替沙格韦单抗-西加韦单抗肌内注射剂用于预防免疫功能低下的 COVID-19 患者的安全性和有效性。
Perm J. 2023 Dec 15;27(4):44-54. doi: 10.7812/TPP/22.180. Epub 2023 Sep 18.
5
Tixagevimab-Cilgavimab: COVID-19 Pre-Exposure Prophylaxis.泰它西单抗-西加韦单抗：COVID-19 暴露前预防。
Clin J Oncol Nurs. 2022 Sep 15;26(5):479-482. doi: 10.1188/22.CJON.479-482.
6
Efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis for COVID-19: A systematic review and meta-analysis.替沙格韦单抗-西加韦单抗作为新型冠状病毒肺炎暴露前预防的疗效和安全性：一项系统评价和荟萃分析
Rev Med Virol. 2023 Mar;33(2):e2420. doi: 10.1002/rmv.2420. Epub 2023 Jan 8.
7
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry.接受替沙格韦单抗/西加韦单抗被动预先暴露免疫的血液系统恶性肿瘤合并 COVID-19 患者：EPICOVIDEHA 登记研究的配对分析。
J Hematol Oncol. 2023 Apr 1;16(1):32. doi: 10.1186/s13045-023-01423-7.
8
Unexpectedly long persistence of anti-SARS-CoV-2 spike monoclonal antibodies tixagevimab and cilgavimab in immunocompromised patients.抗SARS-CoV-2刺突单克隆抗体替沙格韦单抗和西加韦单抗在免疫功能低下患者体内的持续时间意外延长。
Transpl Infect Dis. 2023 Dec;25(6):e14164. doi: 10.1111/tid.14164. Epub 2023 Oct 4.
9
In persons at risk for poor vaccination response or COVID-19 exposure, tixagevimab + cilgavimab reduced COVID-19.在对疫苗反应不佳或有 COVID-19 暴露风险的人群中，替沙格韦单抗联合西加韦单抗可降低 COVID-19 发病率。
Ann Intern Med. 2022 Aug;175(8):JC92. doi: 10.7326/J22-0056. Epub 2022 Aug 2.
10
A Canadian Perspective: Monoclonal Antibodies for Pre- and Post-Exposure Protection from COVID-19 in Vulnerable Patients with Hematological Malignancies.加拿大视角：单克隆抗体在有血液系统恶性肿瘤的脆弱患者中 COVID-19 暴露前和暴露后的预防保护作用。
Curr Oncol. 2022 May 31;29(6):3940-3949. doi: 10.3390/curroncol29060315.
引用本文的文献
1
Pre-Exposure Prophylaxis and Treatment with Tixagevimab/Cilgavimab for COVID-19 among Immunocompromised Pediatric Patients.替沙格韦单抗/西加韦单抗用于免疫功能低下儿科患者的COVID-19暴露前预防和治疗
J Clin Med. 2024 Mar 31;13(7):2029. doi: 10.3390/jcm13072029.
2
Effectiveness of Sotrovimab in Preventing COVID-19-Related Hospitalizations or Deaths Among US Veterans During Omicron BA.1.索托维单抗在预防美国退伍军人中奥密克戎BA.1变异株期间与COVID-19相关的住院或死亡方面的有效性
Open Forum Infect Dis. 2023 Dec 2;10(12):ofad605. doi: 10.1093/ofid/ofad605. eCollection 2023 Dec.
3
Effects of Anti-COVID-19 Vaccination and Pre-Exposure Prophylaxis with Tixagevimab-Cilgavimab in Kidney and Liver Transplant Recipients.肾和肝移植受者中抗 COVID-19 疫苗接种和替沙格韦单抗-西加韦单抗预先暴露预防的效果。
Medicina (Kaunas). 2023 Nov 30;59(12):2101. doi: 10.3390/medicina59122101.
4
Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era.替沙格韦单抗/西加韦单抗作为多发性骨髓瘤患者预防COVID-19的暴露前预防：在奥密克戎时代的一项前瞻性研究
Diseases. 2023 Sep 18;11(3):123. doi: 10.3390/diseases11030123.
5
Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data.替沙格韦单抗/西加韦单抗预防奥密克戎变异株流行期间的 COVID-19：美国退伍军人健康管理局电子数据的回顾性分析。
mBio. 2023 Aug 31;14(4):e0102423. doi: 10.1128/mbio.01024-23. Epub 2023 Aug 3.
6
Public Interest in COVID-19 Therapeutics for High-Risk Populations During the Omicron Era: A Google Trends Analysis.奥密克戎时代公众对高危人群新冠治疗方法的关注度：谷歌趋势分析
Cureus. 2022 Dec 19;14(12):e32684. doi: 10.7759/cureus.32684. eCollection 2022 Dec.
7
Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection.富马酸替诺福韦二吡呋酯/恩曲他滨与 HIV 感染者中 COVID-19 的严重程度。
AIDS. 2022 Dec 1;36(15):2171-2179. doi: 10.1097/QAD.0000000000003372. Epub 2022 Aug 23.
8
Omicron breakthrough infections in patients with immune-mediated inflammatory diseases.免疫介导性炎症疾病患者中的奥密克戎突破性感染
Lancet Rheumatol. 2022 Nov;4(11):e751-e752. doi: 10.1016/S2665-9913(22)00251-X. Epub 2022 Aug 23.
9
Travel in the Time of COVID: A Review of International Travel Health in a Global Pandemic.新冠疫情下的旅行：全球大流行期间国际旅行健康综述
Curr Infect Dis Rep. 2022;24(10):129-145. doi: 10.1007/s11908-022-00784-3. Epub 2022 Aug 4.
10
Patients with Chronic Lymphocytic Leukemia Have a Very High Risk of Ineffective Response to the BNT162b2 Vaccine.慢性淋巴细胞白血病患者对BNT162b2疫苗无反应的风险非常高。
Vaccines (Basel). 2022 Jul 21;10(7):1162. doi: 10.3390/vaccines10071162.
Zotero 插件